These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8610)

  • 1. Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover.
    Snider SR; Hutt C; Stein B; Prasad AL; Fahn S
    J Pharm Pharmacol; 1976 Jul; 28(7):563-6. PubMed ID: 8610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine: a rather specific stimulant of dopamine receptors regulating dopamine metabolism.
    Di Chiara G; Vargiu L; Porceddu ML; Gessa GL
    Adv Biochem Psychopharmacol; 1977; 16():443-6. PubMed ID: 578073
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of three dopamine agonists on cage climbing behavior.
    Gianutsos G; Palmeri JL
    Psychopharmacology (Berl); 1983; 79(4):329-31. PubMed ID: 6134299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential behavioral and biochemical effects of four dopaminergic agonists.
    Gianutsos G; Moore KE
    Psychopharmacology (Berl); 1980; 68(2):139-46. PubMed ID: 6107946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships.
    Widerlöv E; Lewander T
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Sep; 304(2):111-23. PubMed ID: 703854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of alpha-methyltyrosine on brain catecholamine levels and on spontaneous and amphetamine-stimulated motor activity in mice.
    Dominic JA; Moore KE
    Arch Int Pharmacodyn Ther; 1969 Mar; 178(1):166-76. PubMed ID: 5353469
    [No Abstract]   [Full Text] [Related]  

  • 7. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats.
    Tissari AH; Rossetti ZL; Meloni M; Frau MI; Gessa GL
    Eur J Pharmacol; 1983 Aug; 91(4):463-8. PubMed ID: 6413231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
    Silbergeld EK; Pfeiffer RF
    J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats.
    Robertson GS; Robertson HA
    Brain Res; 1986 Oct; 384(2):387-90. PubMed ID: 2946360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.
    Vigouret JM; Bürki HR; Jaton AL; Züger PE; Loew DM
    Pharmacology; 1978; 16 Suppl 1():156-73. PubMed ID: 565520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of acute and chronic administration of morphine on the turnover of brain and adrenal catecholamines in rats.
    Guaza C; Torrellas A; Borrell S; Borrell J
    Psychopharmacology (Berl); 1980; 68(1):43-9. PubMed ID: 6104838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central catecholamine turnover and self-stimulation behaviour.
    Arbuthnott G; Fuxe K; Ungerstedt U
    Brain Res; 1971 Apr; 27(2):406-13. PubMed ID: 5552182
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of AT II on the exploratory behaviour of rats. Interactions with elymoclavine and bromocryptine.
    Petkova B; Georgiev V; Kambourova T
    Acta Physiol Pharmacol Bulg; 1991; 17(2-3):84-90. PubMed ID: 1819920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between amphetamine antagonism and depletion of brain catecholamines by alpha-methyl-p-tyrosine in rats.
    Widerlöv E; Lewander T
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Sep; 304(2):125-34. PubMed ID: 703855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal catecholamine concentration after chronic treatment with bromocriptine and haloperidol.
    Baksi SN; Hughes MJ; Strahlendorf HK
    J Pharm Pharmacol; 1986 Oct; 38(10):774-6. PubMed ID: 2879003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism.
    Kehr W
    Eur J Pharmacol; 1984 Jan; 97(1-2):111-9. PubMed ID: 6421606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243.
    Robertson HA; Peterson MR; Worth GG
    Brain Res; 1992 Oct; 593(2):332-4. PubMed ID: 1360321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine-mediated behaviours produced in naive mice by bromocriptine plus SKF 38393.
    Jackson DM; Ross SB; Hashizume M
    J Pharm Pharmacol; 1988 Mar; 40(3):221-3. PubMed ID: 2899159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central dopaminergic and noradrenergic components of bromocryptine-induced locomotor activity in mice [proceedings].
    Dolphin AC; Jenner P; Marsden CD; Sawaya MC
    Br J Pharmacol; 1977 Mar; 59(3):467P. PubMed ID: 576587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.